Anticoagulant: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Anticoagulants''' are "agents that prevent blood clotting".<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&index=883&field=all&HM=&II=&PA=&form=&input= |title=Anticoagulants |accessdate=2007-12-20 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> They may be used to prevent [[thromboembolism]]. | '''Anticoagulants''' are "agents that prevent [[coagulation|blood clotting]]".<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&index=883&field=all&HM=&II=&PA=&form=&input= |title=Anticoagulants |accessdate=2007-12-20 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> They may be used to prevent [[embolism and thromboembolism]]. | ||
{{editintro}} | {{editintro}} | ||
==Vitamin K antagonists== | ==Vitamin K antagonists== | ||
| Line 9: | Line 9: | ||
==Heparin== | ==Heparin== | ||
Details of the usage of heparin are available in [[clinical practice guideline]]s by the [[American College of Chest Physicians]]<ref name="pmid15383472">{{cite journal |author=Hirsh J, Raschke R |title=Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy |journal=Chest |volume=126 |issue=3 Suppl |pages=188S-203S |year=2004 |pmid=15383472 |doi=10.1378/chest.126.3_suppl.188S}}</ref>: | Details of the usage of heparin are available in [[clinical practice guideline]]s by the [[American College of Chest Physicians]]<ref name="pmid15383472">{{cite journal |author=Hirsh J, Raschke R |title=Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy |journal=Chest |volume=126 |issue=3 Suppl |pages=188S-203S |year=2004 |pmid=15383472 |doi=10.1378/chest.126.3_suppl.188S|url=http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S}}</ref>: | ||
* [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T4 Non-weight based heparin dose adjustment] | * [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T4 Non-weight based heparin dose adjustment] | ||
* [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T5 Weight-based heparin dose adjustment] | * [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T5 Weight-based heparin dose adjustment] | ||
Revision as of 14:07, 24 January 2008
Anticoagulants are "agents that prevent blood clotting".[1] They may be used to prevent embolism and thromboembolism.
[]
Vitamin K antagonists
Warfarin
Warfarin is a commonly used oral anticoagulant that interferes with the Vitamin K dependent coagulation co-factors.
Heparin
Details of the usage of heparin are available in clinical practice guidelines by the American College of Chest Physicians[2]:
Direct thrombin inhibitors
Direct thrombin inhibitors bind directly to thrombin.[3]
- Argatroban is for treating heparin-induced thrombocytopenia (HIT)
- Bivalirudin is a recombinant protein
- Dabigatran
- Desirudin
- Hirudin is a recombinant protein for treating heparin-induced thrombocytopenia (HIT)
- Lepirudin
- Ximelagatran is a recombinant protein that is an oral direct thrombin inhibitor
Factor Xa inhibitors
Idraparinux is a synthetic derivative of heparin that has a long half life that allows once-weekly dosage. A randomized controlled trial compared idraparinux to warfarin and found that idraparinux is equivalent for deep venous thrombosis but is inferior for pulmonary embolism.[4]
References
- ↑ National Library of Medicine. Anticoagulants. Retrieved on 2007-12-20.
- ↑ Hirsh J, Raschke R (2004). "Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest 126 (3 Suppl): 188S-203S. DOI:10.1378/chest.126.3_suppl.188S. PMID 15383472. Research Blogging.
- ↑ Di Nisio M, Middeldorp S, Büller HR (2005). "Direct thrombin inhibitors". N. Engl. J. Med. 353 (10): 1028–40. DOI:10.1056/NEJMra044440. PMID 16148288. Research Blogging.
- ↑ Buller HR, Cohen AT, Davidson B, et al (2007). "Idraparinux versus standard therapy for venous thromboembolic disease". N. Engl. J. Med. 357 (11): 1094–104. DOI:10.1056/NEJMoa064247. PMID 17855670. Research Blogging.
See also
External links
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines